Advances in MR spectroscopy of the prostate.

[1]  J. F. Cooper,et al.  The role of citric acid in the physiology of the prostate: a preliminary report. , 1958, Transactions. American Urological Association. Western Section.

[2]  J F COOPER,et al.  The role of citric acid in the physiology of the prostate. A chromatographic study of citric acid cycle intermediates in benign and malignant prostatic tissue. , 1963, The Journal of surgical research.

[3]  J. F. Cooper,et al.  THE ROLE OF CITRIC ACID IN THE PHYSIOLOGY OF THE PROSTATE. 3. LACTATE/CITRATE RATIOS IN BENIGN AND MALIGNANT PROSTATIC HOMOGENATES AS AN INDEX OF PROSTATIC MALIGNANCY. , 1964, The Journal of urology.

[4]  O Heby,et al.  Role of polyamines in the control of cell proliferation and differentiation. , 1981, Differentiation; research in biological diversity.

[5]  L Axel,et al.  Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. , 1989, Radiology.

[6]  J. Lewin,et al.  Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. , 1989, Radiology.

[7]  R. Franklin,et al.  Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate , 1991, The Prostate.

[8]  R. Franklin,et al.  Concepts of citrate production and secretion by prostate 1. Metabolic relationships , 1991, The Prostate.

[9]  R E Lenkinski,et al.  Prostate cancer: local staging with endorectal surface coil MR imaging. , 1991, Radiology.

[10]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[11]  J. Kurhanewicz,et al.  Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study , 1993, Magnetic resonance in medicine.

[12]  H M Pollack,et al.  Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. , 1993, The Journal of urology.

[13]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[14]  P. Carroll,et al.  Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. , 1994, Radiology.

[15]  R. Franklin,et al.  Bioenergetic theory of prostate malignancy , 1994, The Prostate.

[16]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[17]  P. Carroll,et al.  Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. , 1995, Radiology.

[18]  P. Carroll,et al.  Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. , 1996, AJR. American journal of roentgenology.

[19]  P. Carroll,et al.  Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. , 1996, Urology.

[20]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[21]  J Kurhanewicz,et al.  Prostate carcinoma: MR imaging findings after cryosurgery. , 1996, Radiology.

[22]  R Alagappan,et al.  Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. , 1997, Radiology.

[23]  J Star-Lack,et al.  High spatial resolution and speed in MRSI , 1997, NMR in biomedicine.

[24]  A. Renshaw,et al.  Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. , 1997, Urology.

[25]  J. Srigley,et al.  Interobserver variation in prostate cancer Gleason scoring: are there implications for the design of clinical trials and treatment strategies? , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  P. Carroll,et al.  Focal therapy for prostate cancer 1996: maximizing outcome. , 1997, Urology.

[27]  J A Smith,et al.  Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. , 1997, The Journal of urology.

[28]  A. Pollack,et al.  External beam radiotherapy dose response of prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[29]  J. Kurhanewicz,et al.  Detection of recurrent prostate cancer after cryosurgery. , 1998, Current opinion in urology.

[30]  J Star-Lack,et al.  In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors. , 1998, Journal of magnetic resonance.

[31]  R. Franklin,et al.  Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer , 1998, The Prostate.

[32]  A. Partin,et al.  Ability of sextant biopsies to predict radical prostatectomy stage. , 1998, Urology.

[33]  Josh Star-Lack,et al.  In VivoLactate Editing with Simultaneous Detection of Choline, Creatine, NAA, and Lipid Singlets at 1.5 T Using PRESS Excitation with Applications to the Study of Brain and Head and Neck Tumors☆ , 1998 .

[34]  L Verhey,et al.  Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[35]  J Kurhanewicz,et al.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.

[36]  R. Franklin,et al.  Inhibitory effect of zinc on human prostatic carcinoma cell growth , 1999, The Prostate.

[37]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[38]  M. Deimling,et al.  Combination of signal intensity measurements of lesions in the peripheral zone of prostate with MRI and serum PSA level for differentiating benign disease from prostate cancer , 2000, European Radiology.

[39]  M. Zaider,et al.  Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. , 2000, International journal of radiation oncology, biology, physics.

[40]  H. Hricak,et al.  Radiologic anatomy of the prostate gland: a clinical approach. , 2000, Radiologic clinics of North America.

[41]  J Kurhanewicz,et al.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. , 2000, The Journal of urology.

[42]  J. Kurhanewicz,et al.  Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer , 2000, Magnetic resonance in medicine.

[43]  J Kurhanewicz,et al.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. , 2000, Neoplasia.

[44]  J. Zeng,et al.  Lateral biopsies added to the traditional sextant prostate biopsy pattern increases the detection rate of prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[45]  Bettuzzi Saverio,et al.  Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. , 2000 .

[46]  H. Hricak,et al.  Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. , 2001, Radiology.

[47]  P. Carroll,et al.  Spectroscopy in prostate cancer: hope or hype? , 2001, Oncology.

[48]  J Kurhanewicz,et al.  Time‐dependent effects of hormone‐deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging , 2001, Magnetic resonance in medicine.

[49]  J. Nelson,et al.  Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. , 2001, Cancer research.

[50]  G. Hanks.  Spectroscopy in Prostate Cancer: Hope or Hype? , 2001 .

[51]  A W Partin,et al.  Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.

[52]  B Pickett,et al.  Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. , 2001, International journal of radiation oncology, biology, physics.

[53]  J Kurhanewicz,et al.  Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. , 2001, Radiology.

[54]  J. Pauly,et al.  Dualband spectral‐spatial RF pulses for prostate MR spectroscopic imaging , 2001, Magnetic resonance in medicine.

[55]  N Sailasuta,et al.  Single‐voxel oversampled J‐resolved spectroscopy of in vivo human prostate tissue , 2001, Magnetic resonance in medicine.

[56]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[57]  Cedric Yu,et al.  Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[58]  J. Kurhanewicz,et al.  Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer , 2002, Journal of magnetic resonance imaging : JMRI.

[59]  Kazuto Ito,et al.  MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer. , 2002, Anticancer research.

[60]  P. Walsh,et al.  Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. , 2002, The Journal of urology.

[61]  G L Sannazzari,et al.  CT-MRI image fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer. , 2002, The British journal of radiology.

[62]  M. Kattan,et al.  Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. , 2003, Radiology.

[63]  H. Katoh,et al.  Evaluation of 18F-2-deoxy-2-fluoro-d-glucose Positron Emission Tomography for Gastric Cancer , 2004, World Journal of Surgery.

[64]  Peter Bartenstein,et al.  Overexpression of Glut‐1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma , 2003, Cancer.

[65]  Kazuto Ito,et al.  The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. , 2003, Anticancer research.

[66]  R. Franklin,et al.  Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. , 2003, Journal of inorganic biochemistry.

[67]  Pierre I Karakiewicz,et al.  Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. , 2003, European urology.

[68]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[69]  J. Ardenkjær-Larsen,et al.  Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[71]  J S Petersson,et al.  Molecular imaging using hyperpolarized 13C. , 2003, The British journal of radiology.

[72]  P. Carroll,et al.  Proton HR‐MAS spectroscopy and quantitative pathologic analysis of MRI/3D‐MRSI‐targeted postsurgical prostate tissues , 2003, Magnetic resonance in medicine.

[73]  Jan H. Ardenkjær-Larsen,et al.  Molecular imaging with endogenous substances , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Mark Rijpkema,et al.  Combined quantitative dynamic contrast‐enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer , 2004, Journal of magnetic resonance imaging : JMRI.

[75]  W S Ng,et al.  Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. , 2004, The Journal of urology.

[76]  J. Pauly,et al.  Design of symmetric‐sweep spectral‐spatial RF pulses for spectral editing , 2004, Magnetic resonance in medicine.

[77]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[78]  P. Carroll,et al.  Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. , 2004, Radiology.

[79]  J. Kurhanewicz,et al.  Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. , 2004, International journal of radiation oncology, biology, physics.

[80]  J. Pouliot,et al.  Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. , 2004, International journal of radiation oncology, biology, physics.

[81]  J. Kurhanewicz,et al.  Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. , 2005, Radiology.

[82]  R. Franklin,et al.  ‘Why do tumour cells glycolyse?’: From glycolysis through citrate to lipogenesis , 2005, Molecular and Cellular Biochemistry.

[83]  Peter Magnusson,et al.  13C imaging—a new diagnostic platform , 2005, European Radiology.

[84]  P. Carroll.  Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? , 2005, The Journal of urology.

[85]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[86]  Michael Garwood,et al.  Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T , 2005, Magnetic resonance in medicine.

[87]  M. Zelefsky.  Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer , 2005 .

[88]  C. Siegel.  Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. , 2005, The Journal of urology.

[89]  Franz Wind,et al.  Über den Stoffwechsel von Tumoren im Körper , 1926, Klinische Wochenschrift.

[90]  P. Walsh.  Adult Urology: Urological Survey: Urologic Oncology: Prostate CancerProstate Cancer Localization With Endorectal MR Imaging and MR Spectroscopic Imaging: Effect of Clinical Data on Reader Accuracy , 2005 .

[91]  P. Carroll,et al.  Quantitative analysis of prostate metabolites using 1H HR‐MAS spectroscopy , 2006, Magnetic resonance in medicine.

[92]  A. Villers,et al.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. , 2006, The Journal of urology.

[93]  M. Kattan,et al.  Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. , 2006, Radiology.

[94]  Tom W J Scheenen,et al.  IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. , 2006, International journal of radiation oncology, biology, physics.

[95]  Jan Henrik Ardenkjaer-Larsen,et al.  Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. , 2006, Cancer research.

[96]  John M Pauly,et al.  High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. , 2006, Magnetic resonance imaging.

[97]  E W Steyerberg,et al.  Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. , 2006, The Journal of urology.

[98]  John M Pauly,et al.  Hyperpolarized C‐13 spectroscopic imaging of the TRAMP mouse at 3T—Initial experience , 2007, Magnetic resonance in medicine.

[99]  S J Kohler,et al.  In vivo 13carbon metabolic imaging at 3T with hyperpolarized 13C‐1‐pyruvate , 2007, Magnetic resonance in medicine.

[100]  J. Kurhanewicz,et al.  Monitoring Prostate Cancer Progression in A Transgenic Murine Model Using 3T Hyperpolarized 13 C MRSI , 2007 .

[101]  Michael W Kattan,et al.  Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. , 2007, Radiology.

[102]  John M Pauly,et al.  Double spin-echo sequence for rapid spectroscopic imaging of hyperpolarized 13C. , 2007, Journal of magnetic resonance.

[103]  J. Pouliot,et al.  Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[104]  John Kurhanewicz,et al.  Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. , 2008, Journal of endourology.

[105]  P. Carroll,et al.  Multiparametric magnetic resonance imaging in prostate cancer: present and future , 2008, Current opinion in urology.

[106]  Katarzyna J Macura,et al.  Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. , 2009, Radiology.